Neuroendocrine alterations in lung cancer patients

Neuroendocrinology Letters

Volumn 24, Issue 1-2, 2003, Pages 77-82

  Mazzoccoli, Gianluigi ^a   Carughi, Stefano ^a   De Cata, Angelo ^a   La Viola, Marco ^a   Giuliani, Antonio ^a   Tarquini, Roberto ^b   Perfetto, Federico ^b  

^a Department of Internal Medicine   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cortisol; FT4; GH; IGF I; Lung cancer; Melatonin; Neuro endocrine system; TRH; TSH

Indexed keywords

GROWTH HORMONE; HYDROCORTISONE; MELATONIN; PROTIRELIN; SOMATOMEDIN; THYROTROPIN; THYROXINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE FUNCTION; FREE THYROXINE INDEX; GROWTH HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; NEUROENDOCRINE SYSTEM; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 0038218549     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Brabant G, Prank K, Ranft U, Schuermeyer T, Wagner TOF, Hauser H, Kummer B, Feistner H, Hesch RD, von zur Muhlen A. Physiological regulation of circadian and pulsatile thyrotropin secretion in normal man and women. J Clin Endocrinol Metab 1990; 70:403-9.
2. Bertough JV, Roberts Thomson PJ, Bradley J. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. Br Med J 1983; 286:1171-72.
3. Cugini P, Lucia P, Di Palma L, Pozzilli P, Re M, Canova R, Gasbarrone L, Cianetti A. Temporal interrelationships between circadian rhythms of vasoactive intestinal peptide and T lymphocyte subpopulations. J Clin Lab Immunol 1991; 34:49-54.
4. Cugini P, Cavallini M, Pozzilli P, Letizia C, Sepe M, Di Palma L. Circadian rhythm of T lymphocyte subsets, cortisol and cyclosporin in kidney transplanted subjects. Nephrol Dial Transplant 1991, 6:512-7.
5. Ebadi M. Regulation of the synthesis of melatonin and its significance to neuroendocrinology. In: Reiter R.J.ed. The pineal gland. New York, Raven Press , 1984. pp. 1-37.
6. Ritchie AWS, Oswald I, Micklem HS, Boyd JE, Etton RA, Jazwinska E, James K. Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Br Med J 1983; 286:1773-75.
7. Touitou Y. Effects of ageing on endocrine and neuroendocrine rhythms in humans. Horm Res 1995; 43:12-19.
8. Fauci AS. Mechanism of corticosteroid function on lymphocyte subpopulations.I. Redistribution of circulating T and B lymphocytes to the bone marrow. Immunology 1975; 28:669-80.
9. Fabris N, Mocchegiani E, Provinciali M. Pituitary-thyroid axis and immune system: a reciprocal neuroendocrine-immune interaction. Horm Res 1995; 43:29-38.
10. Reiter RJ. Functional pleiotropy of the neurohormone melatonin, antioxidant protection and neuroendocrine regulation. Front Neuroendocrinol 1995; 16:383-415.
11. Sanchez de La Pena S. The feedsideward of cephalo-adrenal immune interactions. Chronobiologia 1993; 20:1-52.
12. Cardinali PD. Neural-hormonal integrative mechanisms in the pineal gland and superior cervical ganglia. In: Reiter RJ ed. The pineal gland, New York, Raven Press; 1984. 83-101.
13. Weigent DA, Blalock JE. Interactions between the neuroendocrine and immune systems: common hormones and receptors. Immunol Rev 1987; 100:79-84.
14. Bartsch C, Bartsch E, Fuchs U. Stage dependent depression of melatonin in patients with primary breast cancer. Cancer 1989; 64:426-433.
15. Bartsch C, Bartsch H, Karenovics A. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size. J Pineal Res 1997; 23:53-8.
16. Kaver I, Pecht M, Trainin N, Greenstein A, Braf Z. T lymphocyte subsets and function in the peripheral blood of patients with urological cancer. Oncology 1992; 49:108-13.
17. Takahashi M, Fujimoto S, Takai M, Ohno K, Endoh F, Masuda Y, Obata G. Two-color flow cytometric analysis of splenic lymphocyte subpopulations in patients with gastric cancer. SurgToday 1992; 22:35-9.
18. Cartei G, Sala PG, Sanzari M, Ceschia V, Clocchiatti L, Sibau A, Dona S, Giovannoni M, Vigevani E. Reduced lymphocyte subpopulations in patients with advanced or disseminated melanoma. J Am Acad Dermatol 1993; 28:738-44.
19. Jackson PA, Green MA, Marks CG, King RJ, Hubbard R, Cook MG. Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. Gut 1996; 38:85-9.
20. Lores Vazquez B, Pacheco Carracedo M, Oliver Morales J, Parada Gonzalez P, Gambon Deza F. Lymphocyte subpopulations of regional lymph nodes in human colon and gastric adenocarcinomas. Cancer Immunol Immunother 1996; 42:339-42.
21. Chouaib S, Asselin Pasturel C, Mami Chouaib F, Caignard A, Blay JY. The host-tumor immune conflit: from immunosuppression to resistance and destruction. Immunol Today 1997; 18:493-9.
22. Orditura M, Romano C, De Vita F, Galizia G, Lieto E, Infusino S, De Cataldis G, Catalano G. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol. Immunother 2000; 49:530-6.
23. Nelson W, Tong L, Lee JK, Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979; 6:305-323.
24. Halberg F. Quo vadis basic and clinical chronobiology: promise for health maintenance. Quo vadis chronobiology 1983; 8:545-594.
25. Finocchiaro LME, Nahmod VE, Launay JM. Melatonin biosynthesis and metabolism in peripheral blood mononuclear leucocytes. Biochem J 1991; 280:727-731.
26. Brzezinski A. Melatonin in humans. The New Engl J Med 1997; 336:186-95.
27. Grad BR, Rozencwaig R. The role of melatonin and serotonin in aging, update. Psychoneuroendocrinology 1993; 18:283-295.
28. Reiter RJ, Maestroni GJ. Melatonin in relation to the antioxidative defense and immune systems: possible implications for cell and organ transplantation. J Mol Med 1999; 77:36-9.
29. Cardinali DP, Cutrera RA, Esquifino AI. Psychoimmune neuroendocrine integrative mechanisms revisited. Biol Signals Recept 2000; 9:215-30.
30. Fauci AS, Dale DC. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest 1974; 53:240-6.
31. Esposti D, Lissoni P, Tancini G, Barni S, Crispino S, Paolorossi F, Rovelli F, Ferri L, Cattaneo G, Esposti G, Lucini V, Fraschini F. A study on the relationship between the pineal gland and the opioid system in patients with cancer. Cancer 1998; 62:494-499.
32. Lopez Gonzalez MA, Calvo JR, Osuna C, Guerrero JM. Interaction of melatonin with human lymphocytes, evidence for binding sites coupled to potentiation of cyclic AMP stimulated by vasoactive intestinal peptide and activation of cyclic GMP. J Pineal Res 1992; 12:97-104.
33. Maestroni GJM. T-helper-2 lymphocytes as a peripheral target of melatonin. J Pineal Res 1995; 18:84-9.
34. Maestroni GJM, Conti A, Pierpaoli W. The pineal gland and the circadian. opiatergic, immunoregolatory role of melatonin. Ann NYAcad Sci 1987; 496:67-77.
35. Maestroni GJM, Conti A, Pierpaoli W. Melatonin antagonizes the immunosoppressive effect of acute stress via an opiatergic mechanism. Immunology 1988; 63:465-469.
36. Maestroni GJM, Conti A. The pineal nehurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties. JNeuroimmunol 1990; 28:167-176.
37. Lissoni P, Barni S, Crispino S. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 1989; 25:789-795.
38. Lissoni P, Barni S, Archili C. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer. Anticancer Research 1990; 10:753-758.
39. Lissoni P, Barni S, Rovelli F. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin, preliminary results. Eur J Cancer 1993; 29:185-189.
40. Lissoni P. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small lung cancer. Br J Cancer 1992; 66:155-158.
41. Pierpaoli W, Yi C. The involvement of pineal gland and melatonin in immunity and aging. Thymus- mediated, immunorecostituting and antiviral activity of thyrotropin-releasing hormone. J Neuroimmunol 1990, 27:99-109.
42. Clark R. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocrine Reviews 1997; 18:157-179.
43. Bartsch C, Bartsch H. Significance of melatonin in malignant diseases. Wien Klin Wochenschr 1997; 109:722-9.
44. Bartsch C, Bartsch H, Buchberger A. Serial transplants of DMBA-induced mammary tumors in Fischer rats as a model system for human breast cancer. VI. The role of different forms of tumor-associated stress for the regulation of pineal melatonin secretion. Oncology 1999; 56:169-76.
45. Bartsch C, Bartsch H, Schmidt A. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients, evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta 1992; 209:153-167.
46. Dogliotti L, Berruti A, Buniva T, Torta M, Bottini A, Tampellini M, Terzolo M, Faggiuolo R, Angeli A. Melatonin and human cancer. J Ster Biochem Molec Biol 1990; 37:983-987.
47. Mormont M, Hecquet B., Bogdan A, Benavides M, Toitou Y, Levi F. Non invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer 1998; 78:421-24.
48. Grin W, Grunberger W. A significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Invest 1998; 45:62-5.
49. Rosen T, Johansson G, Johansson JO, Bengtsson BA. Consequences of growth hormone deficiency in adults and the risks of recombinant human growth hormone treatment.Horm Res 1995, 43:93-99.
50. Touitou Y, Fevre M, Bogdan A. Circannual rhythm of plasma melatonin in groups of young and elderly humans subjects. Int J Chronobiol 1998; 7:335-9.
51. Touitou Y, Haus E. Alterations with aging of the endocrine and neuroendocrine circadian system in humans. Chronobiol Int 2000; 17:369-90.
52. Waldhauser F, Weiszenbacher G, Tatzer E, Gisinger B, Waldhauser M, Schemper M, Frisch H. Alterations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 1988; 66:648-652.
53. Cullen KJ, Allison A, Martire I, Ellis M, Singer C. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 1992; 22:21-29.
54. Lahm H, Suardet L, Laurent PL, Fischer JR, Ceyhan A, Givel JC, Odartchenko N. Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha. Br J Cancer 1992; 65:341-346.
55. Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68:183-223.
56. Foekens JA, Portengen H, Janssen M, Klijn JG. Insulin-like growth factor-1 receptors and insulin-like growth factor-1 like activity in human primary breast cancer. Cancer 1989; 63:2139-2147.
57. Auernhammer CJ, Strasburger CJ. Effects of growth hormone and insulin-like growth factor on the immune system. Eur J Endocrinol 1995; 133:635-645.
58. Barni S, Lissoni P, Brivio F, Fumagalli L, Merlini D, Cataldo M, Rovelli F, Tancini G. Serum levels of insulin-like growth factor I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin. Tumori 1994; 80:212-215.
59. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL, Cuttitta F. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 1996; 10:11477-11483.
60. Copeland KC, Underwood LE, Van Wyk JJ. Induction of immunoreactive somatomedin C in human serum by growth hormone: dose-response relationships and effect on chromatographic profiles. J Clin Endocrinol Metab 1980; 50:690-697.
61. Jorgensen JOL, Flyvbyerg A, Lauritzen T, Alberti KGMM, Orskov H, Christiansen JS. Dose-response studies with biosynthetic human growth hormone (GH) in GH-deficient patients. J Clin Endocrinol Metab 1988; 67:36-40.
62. Jorgensen JOL, Moller N, Lauritzen T, Alberti KGMM, Orskov H, Christiansen JS. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 1990; 70:207-214.
63. Laursen T, Jorgensen JOL, Jakobsen G, Hansen B, Christiansen JS. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. J Clin Endocrinol Metab 1995; 80:2410-2418,1995.
64. Blum WF, Albertsson Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993; 76:1610-1616.
65. Oscarsson J, Johansson G, Johansson JO, Lundberg PA, Lindstedt G, Bengtsson BA. Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficients adults. Clin Endocrinol 1997; 46:63-68.
66. Stein M, Keller SE, Schleifer SJ. Stress and immunomodulation: the role of depression and neuroendocrine function. J Immunol 1985, 135:8275-52.
67. Smith EM, Phan M, Coppenhaver TE, Kruger TE, Blalock JE. Human lymphocyte production of immunoreactive thyrotropin. Proc Natl Acad Sci USA 1986, 83:2599-605.
68. Harbour DV, Anderson A, Farrington J, Wassef A, Smith EM, Meyer WJ. Decreased mononuclear leukocyte TSH responsiveness in patients with major depression. Biol Psychiatry 1988; 23:727-36.
69. Kruger TE, Smith LR, Harbour DV, Blalock JE. Thyrotropin: an endogenous regulator of the in vitro immune response. J Immunol 1989; 142:744-747